Urmărește-ne
RO
RO

Unul din obiectivele principale ale Life4me+ - să prevină apariția unor noi cazuri de infecție cu HIV, boli cu transmitere sexuală (TBS), hepatită C și tuberculoză

Aplicația permite stabilirea unei comunicări anonime între medici și persoane care au HIV. Îți permite să organizezi mai ușor programul de administrare a tratamentului și să setezi notificări personalizate și discrete

Toate știrile / Martie 2021

Arhivă

✕
24 martie 2021
3191
Lower CD4 counts linked with higher cancer risks in people living with HIV in South Africa

Lower CD4 counts linked with higher cancer risks in people living with HIV in South Africa

A report in Clinical Infectious Diseases has said that immune suppression is linked with an increased risk of numerous cancers amongst people living with HIV, according to data collected and analysed in South Africa. The study’s authors found links between a low CD4 count ...
24 martie 2021
3909
Chinese HIV drug, Aikening, gets first approval outside China

Chinese HIV drug, Aikening, gets first approval outside China

The Republic of Ecuador has become the first country outside of China to authorise the sale and use of a HIV drug developed in China by Frontier Biotech. Aikening (Albuvirtide 160mg) is a new long-acting injectable fusion inhibitor designed to be administered once a week. ...
22 martie 2021
2956
AstraZeneca applies for FDA authorisation after study shows vaccine to be safe and effective

AstraZeneca applies for FDA authorisation after study shows vaccine to be safe and effective

The AstraZeneca vaccine, developed in collaboration with Oxford University, is ‘highly effective’ at preventing COVID-19 in all age groups says the company following a Phase III trial in the US, Chile and Peru. The trial, run by Columbia University and the University ...
22 martie 2021
2764
Long-acting injectable ART is effective for people over 50

Long-acting injectable ART is effective for people over 50

A long-acting injectable antiretroviral treatment (ART), comprised of cabotegravir and rilpivirine, has shown similar levels of efficacy, safety and tolerability in study participants aged over 50 as in those under 50, according to data presented at Conference on Retroviruses ...
21 martie 2021
2853
WHO publishes new guidelines for HIV treatment and care

WHO publishes new guidelines for HIV treatment and care

As the world continues to tackle the ongoing COVID-19 pandemic the World Health Organisation (WHO) is concerned about maintaining the pace and progress in treating and managing HIV. The new recommendations outline key new actions that countries can take to improve the ...
21 martie 2021
2951
TAF and Integrase Inhibitors shown to promote weight gain in people living with HIV

TAF and Integrase Inhibitors shown to promote weight gain in people living with HIV

Tenofovir alafenamide (TAF) promotes weight gain in people who switch HIV treatment regimen according to results from three studies presented at the Conference on Retroviruses and Opportunistic Infections (CROI 2021). The largest study on weight gain so far included a ...
21 martie 2021
2973
Could four-day ART be just as effective as daily ART?

Could four-day ART be just as effective as daily ART?

A four-day on and three-day off HIV antiretroviral treatment (ART) regimen could be just as effective as a daily regimen according to data presented at the Conference on Retroviruses and Opportunistic Infections (CROI 2021). Scientists presented data from the QUATOR study ...
21 martie 2021
3037
The ‘Sao Paulo Patient’ restarts treatment as HIV returns

The ‘Sao Paulo Patient’ restarts treatment as HIV returns

A patient from São Paulo, Brazil, had been maintaining an undetectable viral load for 72 weeks after stopping his antiretroviral therapy (ART), however it was reported at the Conference on Retroviruses and Opportunistic Infections (CROI 2021) that his viral load had increased ...
16 martie 2021
3024
ECDC releases Pre-Exposure Prophylaxis Guidelines

ECDC releases Pre-Exposure Prophylaxis Guidelines

The European Centre for Disease Control and Prevention (ECDC) has issued an operational manual with a raft of recommendations for the design and implementation of Pre-Exposure Prophylaxis (PrEP) programmes. These new guidelines aim to harmonise the efforts of countries ...
15 martie 2021
2909
Dolutegravir-based regimens are more effective than standard HIV treatment for children and adolescents

Dolutegravir-based regimens are more effective than standard HIV treatment for children and adolescents

The international study, ODYSSEY, compared the efficacy and safety of dolutegravir (DTG) – based HIV regimens with standard treatment protocols for children starting first-line or second-line antiretroviral therapy (ART) – the results were presented at the Conference on ...
Folosim cookies pentru a-ți îmbunătăți experiența pe acest site.
Apasând click pe oricare dintre butoane de pe acest site, îți exprimi acordul ca noi să folosim setările din cookies.